Celularity, Inc. (CELU)

NASDAQ: CELU · IEX Real-Time Price · USD
3.07
-0.12 (-3.76%)
At close: Aug 12, 2022 4:00 PM
3.09
+0.02 (0.65%)
After-hours: Aug 12, 2022 6:33 PM EDT
-3.76%
Market Cap 437.24M
Revenue (ttm) 24.61M
Net Income (ttm) -81.45M
Shares Out 142.42M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 731,320
Open 3.21
Previous Close 3.19
Day's Range 3.01 - 3.42
52-Week Range 2.72 - 13.19
Beta 0.16
Analysts Buy
Price Target 12.04 (+292.2%)
Earnings Date Aug 15, 2022

About CELU

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to trea... [Read more...]

Industry Biotechnology
Founded 2016
Employees 225
Stock Exchange NASDAQ
Ticker Symbol CELU
Full Company Profile

Financial Performance

In 2021, Celularity's revenue was $21.34 million, an increase of 49.43% compared to the previous year's $14.28 million. Losses were -$100.12 million, -51.92% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CELU stock is "Buy." The 12-month stock price forecast is 12.04, which is an increase of 292.18% from the latest price.

Price Target
$12.04
(292.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Celularity, Inc. (CELU) Q2 Earnings Beat Estimates

Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 32.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Celularity Reports Second Quarter 2022 Financial Results and Corporate Update

- Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancers -

Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Develop...

CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need

Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining...

- This research collaboration marks Antengene's entry into the field of cellular medicines. SHANGHAI and HONG KONG July 19, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK)...

Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®

FLORHAM PARK, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell the...

5 Growth Stocks That a Volatile Market Can't Stop

These growth stocks have outperformed the broader market by a wide margin this year, delivering outsized gains to shareholders. The post 5 Growth Stocks That a Volatile Market Can't Stop appeared first ...

Other symbols: HALMOSNTROXY

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies Pharmaceutical and Biotech Industry Veteran Brings S...

Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules

FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell ther...

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

FLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a clinical-stage biotechnology company developing placental-derived off-the-shelf all...

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM)

Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell th...

Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the Fir...

CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need

Is Celularity, Inc. (CELU) Outperforming Other Medical Stocks This Year?

Here is how Celularity, Inc. (CELU) and AmerisourceBergen (ABC) have performed compared to their sector so far this year.

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the Firs...

CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Other symbols: APTOCNSPCYADSPRB

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Trea...

FLORHAM PARK, N.J., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today ...

Here's Why Celularity, Inc. (CELU) is Poised for a Turnaround After Losing 34.3% in 4 Weeks

Celularity, Inc. (CELU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti...

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cel...

FLORHAM PARK, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its placental-derived allogeneic genetically modified...

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK...

CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with antibody therapeutics

Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immun...

FLORHAM PARK, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human place...

Celularity Reports Third Quarter 2021 Financial Results and Corporate Update

FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today ...

Celularity Appoints Andrew L. Pecora, M.D.

Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years' experience developing life-changing cellular medicines Renowned clinician, scientist an...

Celularity Reports Second Quarter 2021 Financial Results

FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies...

Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CA...

SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nasdaq: CELU)...

Why GX Acquisition Stock Soared Today

The SPAC closed its merger with clinical-stage biotech Celularity.